At the annual National Cherry Blossom Festival this year, which wrapped up this past weekend, Japanese drugmaker Daiichi Sankyo went back to visit the roots it planted in the nation’s capital ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Free Report) was the target of a significant growth in short interest in March.As of March 31st, there was short interest totalling 184,100 ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

SEATTLE, April 15, 2025 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company targeting RNA with small molecules, announced today a collaboration with Daiichi Sankyo focused on a key ...

Amid these market pressures, the company's collaboration with Daiichi Sankyo was highlighted by the announcement of successful phase 3 trial results for ENHERTU, which positively impacts the ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

The division bench of the Delhi High Court on Tuesday sought response from Japanese pharma major Daiichi Sankyo Company Ltd on the RHC Healthcare Management Services' appeal challenging sale of its ...

Without providing specific data, AstraZeneca and Daiichi Sankyo noted that the Enhertu combo elicited a “highly statistically significant and clinically meaningful improvement” in progression-free ...